摘要
Translational research on immune checkpoint inhibitors (ICIs) has been underway. However, in the unselected population, only a few patients benefit from ICIs. Therefore, screening predictive markers of ICI efficacy has become the current focus of attention. We collected mutation and clinical data from an ICI-treated non-small cell lung cancer (NSCLC) cohort. Then, a univariate Cox regression model was used to analyze the relationship between tumor necrosis factor alpha signaling mutated (TNF alpha-MT) and the prognosis of immunotherapy for NSCLC. We retrospectively collected 36 NSCLC patients (local-cohort) from the Zhujiang Hospital of Southern Medical University and performed whole-exome sequencing (WES). The expression and mutation data of The Cancer Genome Atlas (TCGA)-NSCLC cohort were used to explore the association between TNF alpha-MT and the immune microenvironment. A local cohort was used to validate the association between TNF alpha-MT and immunogenicity. TNF alpha-MT was associated with significantly prolonged overall survival (OS) in NSCLC patients after receiving immunotherapy. Additionally, TNF alpha-MT is related to high immunogenicity (tumor mutational burden, neoantigen load, and DNA damage response signaling mutations) and enrichment of infiltrating immune cells. These results suggest that TNF alpha-MT may serve as a potential clinical biomarker for NSCLC patients receiving ICIs.
学科与关键词
- ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancerZhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, JianCancer Immunology, Immunotherapy, 2021, 70(1): 137-151.被引 60
- B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic AnalysisLin, Anqi; Fang, Jianbo; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*Journal of Inflammation Research, 2022, 15.
- Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint InhibitorsWen, Yang; Lin, Anqi; Zhu, Weiliang; Wei, Ting; Luo, Peng*; Guo, Linlang*; Zhang, Jian*Frontiers in Pharmacology, 2021, 12: 645862.被引 4
